巴瑞替尼治疗生物制剂耐药的成人Still 病和未分化系统性自身炎症性疾病的疗效不一。
Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
机构信息
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Institue of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
出版信息
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001246.
Abstract
This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still's disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of infection following baricitinib use.
摘要
本临床病例系列描述了我们在 2 例难治性成人Still 病（AOSD）患者和 1 例骨髓增生异常综合征相关 AOSD 样自身炎症性疾病患者中使用 Janus 激酶 1/2 抑制剂巴瑞替尼的经验。所有患者均对常规疾病修饰抗风湿药物（DMARDs）和包括白细胞介素（IL）-1 和 IL-6 阻断在内的生物疗法反应不佳，反而依赖于大剂量的泼尼松龙。我们还报告了首例使用巴瑞替尼后感染的病例。
相似文献
1
Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001246.
2
A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic Lesions.
Drugs R D. 2024 Sep;24(3):391-394. doi: 10.1007/s40268-024-00487-1. Epub 2024 Sep 18.
3
Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy.
Rheumatology (Oxford). 2019 Apr 1;58(4):736-737. doi: 10.1093/rheumatology/key414.
4
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease.
Drugs R D. 2023 Jun;23(2):109-120. doi: 10.1007/s40268-023-00417-7. Epub 2023 Apr 3.
5
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2019-001095.
6
Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
Dermatol Ther. 2019 Sep;32(5):e13041. doi: 10.1111/dth.13041. Epub 2019 Aug 12.
7
Adult-onset Still's disease: Advances in the treatment.
Best Pract Res Clin Rheumatol. 2016 Apr;30(2):222-238. doi: 10.1016/j.berh.2016.08.003. Epub 2016 Oct 5.
8
[Adult-onset Still's disease].
Dtsch Med Wochenschr. 2011 Aug;136(33):1669-73. doi: 10.1055/s-0031-1281572. Epub 2011 Aug 10.
9
[Anakinra in refractory adult onset Still's disease].
Ned Tijdschr Geneeskd. 2011;155(18):A2966.
10
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.
引用本文的文献
1
Fatal Acute Intestinal Obstruction with Hemophagocytic Lymphohistiocytosis and Multiple Organ Failure in Adult-Onset Still's Disease: A Rare Case Report.
J Inflamm Res. 2025 Apr 16;18:5161-5171. doi: 10.2147/JIR.S509898. eCollection 2025.
2
Undifferentiated autoinflammatory disease in adults: a prospective study in 61 patients.
Orphanet J Rare Dis. 2025 Apr 8;20(1):165. doi: 10.1186/s13023-025-03685-5.
3
Adult-Onset Still's Disease (AOSD)-On the Basis of Own Cases.
Biomedicines. 2024 Sep 10;12(9):2067. doi: 10.3390/biomedicines12092067.
4
A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic Lesions.
Drugs R D. 2024 Sep;24(3):391-394. doi: 10.1007/s40268-024-00487-1. Epub 2024 Sep 18.
5
Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.
Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):45-57. doi: 10.31138/mjr.290323.dat. eCollection 2024 Mar.
6
Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.
Drugs. 2024 Mar;84(3):257-274. doi: 10.1007/s40265-024-01993-x. Epub 2024 Mar 5.
7
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study.
Front Med (Lausanne). 2023 Nov 15;10:1257045. doi: 10.3389/fmed.2023.1257045. eCollection 2023.
8
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease.
Drugs R D. 2023 Jun;23(2):109-120. doi: 10.1007/s40268-023-00417-7. Epub 2023 Apr 3.
9
Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment.
Int J Mol Sci. 2022 Oct 24;23(21):12810. doi: 10.3390/ijms232112810.
10
Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.
Front Med (Lausanne). 2022 Aug 22;9:881431. doi: 10.3389/fmed.2022.881431. eCollection 2022.
本文引用的文献
1
Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
Ann Rheum Dis. 2020 Jun;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699. Epub 2020 Feb 20.
2
Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
Autoimmun Rev. 2019 Jan;18(1):36-42. doi: 10.1016/j.autrev.2018.07.009. Epub 2018 Nov 5.
3
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.
4
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.
5
Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.
JCI Insight. 2016 May 5;1(6):e86336. doi: 10.1172/jci.insight.86336.
6
Autoimmunity and Inflammation in Myelodysplastic Syndromes.
Acta Haematol. 2016;136(2):108-17. doi: 10.1159/000446062. Epub 2016 Jun 24.
7
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.
8
Adult onset Still's disease associated with malignancy-Cause or coincidence?
Semin Arthritis Rheum. 2016 Apr;45(5):621-6. doi: 10.1016/j.semarthrit.2015.10.003. Epub 2015 Oct 22.
9
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Ann Rheum Dis. 2014 Sep;73(9):1626-34. doi: 10.1136/annrheumdis-2013-204405. Epub 2013 Dec 2.
10
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.
BMC Musculoskelet Disord. 2011 Jul 7;12:153. doi: 10.1186/1471-2474-12-153.
Zotero 插件